MBX Biosciences, Inc. (MBX) Stock Analysis
A live, multi-source view of MBX Biosciences, Inc. (MBX): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Sector: Healthcare · Industry: Biotechnology · United States · 63 employees · mbxbio.com
Key statistics · as of 2026-09-05
As of 2026-09-05, MBX Biosciences, Inc. (MBX) had a market capitalization of $2.97B (forward -15.6); the shares traded in a 52-week range of $9.63 – $72.64 (463.5% over the year).
- Market cap
- $2.97B
- Enterprise value
- $2.56B
- Forward P/E
- -15.6
- Price / book
- 7.23
- EPS (trailing)
- $-2.37
- EPS (forward)
- $-3.96
- Payout ratio
- 0.0%
- 52-week range
- $9.63 – $72.64
- 52-week change
- 463.5%
- Average volume
- 749,200
- Shares outstanding
- 48.2M
- Short % of float
- 14.35%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, MBX Biosciences, Inc. (MBX) last closed at $61.72 (the last completed close before that scan).
Technicals at the scan: RSI 44 (neutral territory), price -5.7% versus its 20-day average, 20-day versus 50-day average spread +3.9%, MACD histogram -1.08.
Sentiment inputs: StockTwits 88% bullish; analyst consensus score 81/100.
Next scheduled company event: in 58 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of MBX; corporate insiders filed 0 buys and 1 sell (1 filer, latest disclosure 2026-08-05). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Salomon Azoulay (0B/1S). Who is trading what
RapidTradeView pick record
MBX has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls MBX Biosciences, Inc. (MBX) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell MBX.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.